Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 20
Age Group: 20 Years to 75 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 10512|H3E-JE-ME02
Study First Received: October 10, 2006
Last Updated: April 10, 2007
Estimated Primary Completion Date: null
Primary Outcome Measures:
To investigate safety profile when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients|To investigate efficacy when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients
Sponsors and Collaborators:
Eli Lilly and Company
Website Link: https://ClinicalTrials.gov/show/NCT00386815
